Address: 19th Floor, Asia Center Building 173/20 South Sathorn Road,Thungmahamek, Sathorn, Bangkok, 10120,Thailand
Tel: 66 2 739 7400
Web: http://www.astrazeneca.co.th/
As a global biopharmaceutical company, our activities touch many people’s lives.
For patients and physicians, we provide medicines for some of the world’s most serious diseases. For the people who pay for healthcare, we work to make sure that our medicines offer real value for money. For our employees, we provide a culture in which they can feel appreciated, energised and rewarded for their contribution. For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently. For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business.
We work closely with all our stakeholders to understand their challenges and how we can combine our skills and resources to achieve a common goal: improved health.
Cardiovascular
CV disease remains the greatest risk to life for adults, accounting for 17 million deaths worldwide each year.
Gastrointestinal
In the West (i.e. Europe and North America) between 10-20% of adults suffer from GERD. The prevalence of GERD in Asia is lower, but increasing.
Infection
World demand for antibiotics remains high, due to escalating resistance and the increased risk of serious infections in both immunosuppressed patients and ageing populations.
Neuroscience
Disorders of the central nervous system are the most significant disease burden in high income countries and is expected to grow substantially in other regions of the world, including Asia, as the standard of living increases.
Oncology
Cancer claims over 7 million lives every year and the number continues to rise. Deaths are estimated to reach 12 million by 2030.
Respiratory
Chronic obstructive pulmonary disease is the fourth leading cause of death worldwide and further increases are anticipated. An estimated 300 million people suffer from asthma.
Dr. Seeto, this is your first head of country position for AZ! Looking back at your first year-and-a-month, what have been the highlights and the key lessons learnt? Firstly, leading…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical…
Takeda’s Soon Yee Chow and Helene Sou, writing in the September 2022 edition of DIA’s Global Forum magazine, outline how digitalisation initiatives, if properly enacted, can help the ASEAN region…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now. Thailand is in the midst of an economic transformation with healthcare at its heart. With four years…
Shinsuke Yuasa, president of Thai Otsuka discusses the importance of Thailand for Otsuka as its first overseas market back in 1973. Yuasa goes on to highlight how the affiliate is…
Thailand country managers from three of the world’s largest medtech firms outline the level of innovation they are able to bring to the Thai market, how their technology is helping…
Nico Form-Zuellig, general manager of Interthai Pharmaceutical Manufacturing, shares his thoughts on the Thai pharmaceutical market as a newcomer to the country and goes on to elaborate on the company’s…
Philippe Pedeboscq, managing director of Siemens Healthineers, shares his impressions after taking the lead of the company’s Thailand affiliate two years ago. Pedeboscq goes on to explain his strategic mission…
Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of the fastest-growing pharma multinationals in Thailand. Upon this solid foundation, Novo…
Nares Damrongchai has been the CEO of the Thailand Center of Excellence for Life Science (TCELS) since its foundation in 2004. After seven years onboard, he discusses the organization’s progress…
See our Cookie Privacy Policy Here
